Nothing about the recent past, present, or foreseeable future seems all that compelling.

The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current price still feels rich, this article walks through what the numbers actually ...

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future.. Citing four unnamed people "familiar with the situation," this effort will be based on ...

BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock ...

BioNTech faces a pivotal strategic shift as its founding leadership prepares to depart and recent financial results disappoint the market. The dual announcements on March 10th sent the company's ...

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE's share was trading at $103.80 as of March 4th.

The company’s co-founders said they are leaving to start a new mRNA-based company.

Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather ...